Dynamic ordering design for dose finding in drug-combination trials.

Drug-combination studies have become increasingly popular in oncology. One of the critical concerns in phase I drug-combination trials is the uncertainty in toxicity evaluation. Most of the existing phase I designs aim to identify the maximum tolerated dose (MTD) by reducing the two-dimensional searching space to one dimension via a prespecified model or splitting the two-dimensional space into multiple one-dimensional subspaces based on the partially known toxicity order. Nevertheless, both strategies often lead to complicated trials which may either be sensitive to model assumptions or induce longer trial durations due to subtrial split. We develop two versions of dynamic ordering design (DOD) for dose finding in drug-combination trials, where the dose-finding problem is cast in the Bayesian model selection framework. The toxicity order of dose combinations is continuously updated via a two-dimensional pool-adjacent-violators algorithm, and then the dose assignment for each incoming cohort is selected based on the optimal model under the dynamic toxicity order. We conduct extensive simulation studies to evaluate the performance of DOD in comparison with four other commonly used designs under various scenarios. Simulation results show that the two versions of DOD possess competitive performances in terms of correct MTD selection as well as safety, and we apply both versions of DOD to two real oncology trials for illustration.

[1]  Ying Yuan,et al.  BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS. , 2011, The annals of applied statistics.

[2]  R Simon,et al.  Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Adrian P Mander,et al.  A product of independent beta probabilities dose escalation design for dual-agent phase I trials , 2015, Statistics in medicine.

[4]  X. Paoletti,et al.  Designs of drug-combination phase I trials in oncology: a systematic review of the literature. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  John O'Quigley,et al.  Continual Reassessment Method for Partial Ordering , 2011, Biometrics.

[6]  G. Rosner,et al.  Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee , 2014, Clinical Cancer Research.

[7]  Ying Yuan,et al.  A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents , 2009, Biometrics.

[8]  Guosheng Yin,et al.  Nonparametric overdose control with late-onset toxicity in phase I clinical trials. , 2017, Biostatistics.

[9]  S. Zohar,et al.  Competing designs for drug combination in phase I dose‐finding clinical trials , 2015, Statistics in medicine.

[10]  A. Venook,et al.  Design Issues in Dose-Finding Phase I Trials for Combinations of Two Agents , 2009, Journal of biopharmaceutical statistics.

[11]  Guosheng Yin,et al.  Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials , 2016 .

[12]  Guosheng Yin,et al.  Bayesian optimal interval design for dose finding in drug-combination trials , 2017, Statistical methods in medical research.

[13]  G. Yin,et al.  Non‐parametric overdose control for dose finding in drug combination trials , 2019, Journal of the Royal Statistical Society: Series C (Applied Statistics).

[14]  W. M. Smit,et al.  Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer , 2015, Investigational New Drugs.

[15]  Anastasia Ivanova,et al.  Two‐Dimensional Dose Finding in Discrete Dose Space , 2005, Biometrics.

[16]  Ying Yuan,et al.  Bayesian dose finding in oncology for drug combinations by copula regression , 2009 .

[17]  M. Sznol,et al.  Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies , 2016, Cancer Chemotherapy and Pharmacology.

[18]  Kai Wang,et al.  A non‐parametric approach to the design and analysis of two‐dimensional dose‐finding trials , 2004, Statistics in medicine.

[19]  Ying Yuan,et al.  Sequential continual reassessment method for two‐dimensional dose finding , 2008, Statistics in medicine.

[20]  Peter F Thall,et al.  Dose‐Finding with Two Agents in Phase I Oncology Trials , 2003, Biometrics.

[21]  Michael J. Sweeting,et al.  Adaptive designs for dual-agent phase I dose-escalation studies , 2013, Nature Reviews Clinical Oncology.

[22]  J. Leeuw,et al.  Isotone Optimization in R: Pool-Adjacent-Violators Algorithm (PAVA) and Active Set Methods , 2009 .

[23]  Alexia Iasonos,et al.  Adaptive dose-finding studies: a review of model-guided phase I clinical trials. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Ying Yuan,et al.  Bayesian optimal interval designs for phase I clinical trials , 2015, Journal of the Royal Statistical Society: Series C (Applied Statistics).

[25]  Ying Yuan,et al.  A Bayesian dose‐finding design for drug combination clinical trials based on the logistic model , 2014, Pharmaceutical statistics.

[26]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[27]  A Kramar,et al.  Continual reassessment methods in phase I trials of the combination of two drugs in oncology. , 1999, Statistics in medicine.